Group 1 - The core viewpoint of the article highlights that 加科思-B (01167) experienced a significant stock price increase of over 16% following the release of its interim results, with a current price of 9.45 HKD and a trading volume of 97.6885 million HKD [1] - The company reported a revenue of 45.664 million RMB for the period, compared to zero revenue in the same period last year, indicating a positive growth trajectory [1] - The loss attributable to the company's owners narrowed by 65.1% to 58.994 million RMB, reflecting improved financial performance [1] Group 2 - The revenue growth was primarily driven by milestone payments from the艾力斯 licensing agreement [1] - The company’s clinical candidate HER2-STING iADC, JAB-BX467, is set to be nominated in the second half of 2024, with plans to submit an IND application in 2026 [1] -艾力斯 has obtained exclusive rights for the research, development, production, registration, and commercialization of the KRAS G12C inhibitor, Goresitib, in China, which is aimed at treating advanced solid tumors with KRAS G12C mutations [1]
港股异动 | 加科思-B(01167)绩后涨超16% 戈来雷塞获批上市 公司中期收入增加至4570万元